Glucocorticoid-Induced Osteoporosis: The Most Common Drug-Related Cause of Bone Loss

A 2018 review published in Endocrine provided an updated overview of glucocorticoid-induced osteoporosis (GIOP), the most common iatrogenic cause of secondary bone loss. Approximately 1% of the adult population uses glucocorticoids chronically, with particularly high rates among older adults managing conditions like rheumatoid arthritis, asthma, COPD, and inflammatory bowel disease. The bone effects are swift and severe: studies show a 6 to 12% decline in lumbar spine bone mineral density in the first year of therapy, with fracture risk increasing within just three to six months of initiation. Over the long term, fractures occur in 30 to 50% of patients on chronic glucocorticoid therapy.

The mechanism is a double hit. Glucocorticoids suppress bone formation by inhibiting osteoblast activity while simultaneously stimulating bone resorption through increased osteoclast signaling. They also reduce calcium absorption in the gut, promote renal calcium wasting, and suppress gonadal hormones — compounding the direct skeletal effects with systemic hormonal disruption.

Why This Matters for Midlife Health

For anyone in midlife already dealing with age-related or menopause-related bone loss, adding a glucocorticoid prescription can dramatically accelerate the problem. The challenge is that many patients on chronic steroids are never assessed for osteoporosis risk, never offered bone-protective co-therapy, and never get a baseline DXA scan before starting treatment. This represents a clear, fixable gap in care — one where patient awareness and self-advocacy can make a measurable difference.

The Tracking Connection

Medication tracking is a core function of Kairos™ for exactly this reason. If you are prescribed a glucocorticoid — even a short course — logging it creates a record that connects to your bone health timeline. When you can show a provider that you have been on prednisone for six months alongside your DXA history and symptom log, the conversation about bone-protective strategies happens because the data makes it unavoidable. Secondary osteoporosis is preventable when it is anticipated, and anticipation starts with tracking.